Drug Trial Radar · NCT00048165
A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation
Last checked: Nov 20, 2026Latest source record: Jun 13, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
434
Actual
Start
Aug 1999
Primary completion
Aug 2002
Study completion Aug 2002
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Oct 25, 2002
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to compare the number of randomized participants in each treatment group who experience an acute rejection episode in the first 6 months after undergoing cardiac transplantation.
Conditions
- Heart Transplantation
Interventions
DaclizumabDrug
Daclizumab will be administered as 1 mg/kg IV within 12 hours post-op (Day 1), and Days 8, 22, 36 and 50.
MethylprednisoloneDrug
Methylprednisolone will be administered as 500-1000 mg IV and peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering till 0.0-0.15 mg/kg/day (up to 365 days).
Mycophenolate mofetilDrug
Mycophenolate mofetil will be administered as 1.5 grams bid begun post-op, either IV or orally as required up to 365 days.
PlaceboDrug
Matching placebo will be administered on Days 1, 8, 22, 36, and 50.
cyclosporineDrug
Cyclosporine will be administered as 1-4 mg/kg IV or 2-6 mg/kg orally up to 365 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Developed Acute Rejection Episode Within 6 Months Post-TransplantTime frame: Up to 6 months PT
Locations
30 sites in 4 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Los Angeles, California
Site not named
Tampa, Florida
Site not named
Louisville, Kentucky
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
Boston, Massachusetts
Site not named
Ann Arbor, Michigan
Site not named
Minneapolis, Minnesota
Site not named
Albuquerque, New Mexico
Site not named
New York, New York
Site not named
Durham, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Cleveland, Ohio
Site not named
Portland, Oregon
Site not named
Philadelphia, Pennsylvania
Site not named
Philadelphia, Pennsylvania
Site not named
Pittsburgh, Pennsylvania
Site not named
Charleston, South Carolina
Site not named
Dallas, Texas
Site not named
Dallas, Texas
Site not named
Houston, Texas
Site not named
Salt Lake City, Utah
Site not named
Madison, Wisconsin
Site not named
Milwaukee, Wisconsin
Site not named
London, Ontario, Canada
Site not named
Ottawa, Ontario, Canada
Site not named
Frankfurt am Main, Germany
Site not named
Hanover, Germany
Site not named
Gothenburg, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.